Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?
We recently published a list of the 10 Best Mid Cap Biotech Stocks to Buy. In this article, we are going to take a look at ...
Barron's Bounce: Sarepta's Soaring Fortunes
The biotech stock's shares surged after Barron's said the market is underestimating potential sales of its Duchenne Muscular ...
Zacks Investment Research on MSN2d
Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?
It has been about a month since the last earnings report for Sarepta Therapeutics (SRPT). Shares have lost about 30.3% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
The Associated Press on MSN12d
Patient dies following muscular dystrophy gene therapy, Sarepta reports
Dec. 10, 2020. (AP Photo/Manuel Balce Ceneta, File) Updated [hour]:[minute] [AMPM] [timezone], [monthFull] [day], [year] ...
Bronstein, Gewirtz & Grossman, LLC Is Investigating Sarepta Therapeutics, Inc. (SRPT) And Encourages Stockholders to Connect
NEW YORK, NY / ACCESS Newswire / March 24, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on ...
Gene-Therapy Maker Sarepta Tanks After Patient Death
Shares of Sarepta Therapeutics have struggled for the past year due to concerns about the commercial potential of its gene ...
Teen’s death following Sarepta DMD gene therapy underscores a risk seen for decades
The death of a 16-year-old boy evokes a lengthy battle to realize the benefit of cutting-edge gene therapy while also ...
Neurology Advisor2d
Patient Dies Following Treatment With DMD Gene Therapy Elevidys
Sarepta Therapeutics announced that a patient with Duchenne muscular dystrophy who received Elevidys (delandistrogene moxeparvovec-rokl) died following treatment.
Sarepta’s stock slammed after patient dies of liver failure. Here’s what Wall Street is saying.
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
GEN - Genetic Engineering and Biotechnology News2d
Dravet Gene Therapy Tested in Mice, Sarepta’s Setback, and AstraZeneca Updates
Listed below are links to the GEN stories reference in this episode of Touching Base Gene Therapy Tested in Mice Offers New ...
Sarepta says teen died after its gene therapy treatment
Sarepta Therapeutics said on Tuesday that a 16-year-old boy died from acute liver failure months after receiving the company's U.S-approved gene therapy for a rare muscular dystrophy.
Wave Life Sciences to submit Duchenne drug for approval after Phase 2 success
The Cambridge-based biotech's experimental treatment for Duchenne muscular dystrophy hit the mark in a mid-stage study, ...